… as an outpatient treatment in a Phase II trial. The Phase … the US Food and Drug Administration (FDA) in May 2023. … axicabtagene ciloleucel) and Roche’s MabThera (rituximab). B-cell lymphoma … you deserve! The Clinical Trials Arena Excellence Awards celebrate …

… , the FDA typically requires two positive pivotal trials to support … #39;s Avastin/MabThera) is only indicated for cancer … studies – have variations in drug concentration that could affect … first-line anti-VEGF treatments in Europe, with approximately …

… compared the combination to MabThera/Rituxan (rituximab), … profiles of the individual trial medicines. Lunsumio and Polivy … bispecific antibody and antibody-drug conjugate, which could … content on Pharmaceutical Technology (or Clinical Trials Arena) is …

… the phase 3 AQUILA trial of the drug, which showed a progression … the New England Journal of Medicine. HR-SMM is a … months without any active treatment. If the FDA approves Darzalex Faspro for … 's anti-CD20 antibody MabThera/Rituxan (rituximab) plus …

… STARGLO trial (NCT04408638), the FDA’s Oncologic Drugs Advisory Committee … PhD, Roche chief medical officer and head of … trial compared the efficacy and safety of Columvi plus GemOx versus MabThera … effective, readily available treatment options and the …

… US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee ( … randomised, multiregional clinical trial, supporting its recent … with other medicines for the treatment of diffuse … Polivy (polatuzumab vedotin) and MabThera/Rituxan (rituximab), …

… overall survival (OS) improvement versus MabThera/Rituxan (rituximab) and GemOx … treatment advances have been made, challenges with the accessibility of existing medicines … offers an ‘’off-the-shelf’’ treatment regimen, readily available for infusion …

… 's anti-CD20 antibody MabThera/Rituxan (rituximab) plus chemo … cell transplant (ASCT). The US FDA is due to make a … running the Epcore DLBCL-4 trial, which is testing Epkinly plus … is that its drug uses a fixed duration of treatment, while AbbVie …

… positive opinion by the European Medicines Agency (EMA)’s Committee … Jaypirca was one of 16 drugs for which CHMP extended therapeutic … in a randomized Phase III trial in this patient population, … , for treatment of not only CLL but also rheumatoid arthritis, in …

… with Polivy (polatuzumab vedotin) and MabThera/Rituxan, cyclophosphamide, doxorubicin and … gemcitabine plus oxaliplatin (GemOx) versus MabThera/Rituxan (rituximab) in combination … in combination with other medicines for the treatment of diffuse large B …